MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$2,959K
Net Income
-$23,785K
Net Profit Margin
-803.82%
EPS
-$0.84
Unit: Thousand (K) dollars
Revenue Breakdown
Biomedical Advanced Research And...
Csl Seqirus
Gates Foundation
Other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
2,959
2,061
7,197
17,151
Research and development, net
17,515
21,527
24,475
23,265
General and administrative
10,989
9,465
14,028
10,398
Total operating expenses
28,504
30,992
38,503
33,663
Loss from operations
-25,545
-28,931
-31,306
-16,512
Gain (loss) from foreign currency
-
-
700
-170
Finance income, net
1,819
1,932
-
-
Other expense
-59
35
1,523
3,234
Net loss before income taxes
-23,785
-
-29,083
-13,448
Provision for income taxes
0
-
-
-
Net loss
-23,785
-26,964
-29,079
-13,448
Comprehensive loss
-23,785
-26,964
-29,079
-13,448
Basic EPS
-0.84
-0.95
-1.034
-0.49
Diluted EPS
-0.84
-0.95
-1.034
-0.49
Basic Average Shares
28,423,000
28,421,000
28,120,000
27,188,000
Diluted Average Shares
28,423,000
28,421,000
28,120,000
27,188,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$23,785K
(-159.10%↓ Y/Y)
Net loss
-$23,785K
(-159.10%↓ Y/Y)
Biomedical Advanced
Research And Development...
$1,369K
(-63.89%↓ Y/Y)
Gates Foundation
$710K
Csl Seqirus
$874K
(-96.42%↓ Y/Y)
Other
$6K
(-92.77%↓ Y/Y)
Net loss before
income taxes
-$23,785K
(-159.21%↓ Y/Y)
Finance income, net
$1,819K
(-29.14%↓ Y/Y)
Grant
$2,079K
(-45.16%↓ Y/Y)
Collaboration Revenue
$880K
(-96.41%↓ Y/Y)
Loss from operations
-$25,545K
(-119.91%↓ Y/Y)
Total revenue
$2,959K
(-89.54%↓ Y/Y)
Other expense
-$59K
(-102.30%↓ Y/Y)
Total operating
expenses
$28,504K
(-28.59%↓ Y/Y)
Research and
development, net
$17,515K
(-40.79%↓ Y/Y)
General and
administrative
$10,989K
(6.30%↑ Y/Y)
Buy us a coffee
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)